Phase 2 Breast Cancer Trial, Not Yet Recruiting
voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice
Who may and may not be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who may be able to join
- People who have been diagnosed with invasive breast cancer confirmed through laboratory tissue testing.
- People whose blood tests show traces of cancer DNA (called ctDNA) after completing their main cancer treatments.
- People who have had surgery to remove the breast cancer, with the lymph nodes under the arm also assessed.
- People whose cancer is hormone receptor-positive and HER2-negative (a specific cancer type based on lab results).
- People whose cancer and lymph node results meet certain defined risk levels set out by the trial (confirm with trial site).
- People who are generally well enough to carry out daily activities with little or no limitation, as measured by a standard medical scale (ECOG performance status of 0 or 1).
- People who do not have cancer in both breasts.
- People who have recovered sufficiently from previous treatments and whose organ function (such as liver and kidneys) is within acceptable levels.
- People who had no signs of cancer spread to distant parts of the body before joining the trial.
- People who are using appropriate contraception and who have given their formal written agreement to take part.
Who may not be able to join
Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.
- People who currently have another active cancer diagnosis.
- People who have previously been treated with a type of drug called a CDK4/6 inhibitor.
- People who have had a major surgical procedure recently or who have an active infection at the time of joining.
- People with blood pressure that is not well controlled, or who have a serious heart condition.
- People who have recently experienced a blood clot in a vein or artery (thromboembolic event).
- People with a lung condition involving inflammation of the lung tissue (interstitial lung disease or active pneumonitis).
- People who still have side effects from previous cancer treatments that have not fully resolved.
- People with an active HIV, hepatitis B, or hepatitis C infection.
- People who are pregnant or currently breastfeeding.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Ryuta Asada, PhD, Nagoya City University
Phone: +81-52-851-5511
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
ctDNA clearance rate
Can't join this trial?
Data last synced from ClinicalTrials.gov: 31 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.